Is Cytomegalovirus Testing of Blood Products Still Needed for Hematopoietic Stem Cell Transplant Recipients in the Era of Universal Leukoreduction?

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 12, 2013, Pages 1719-1724

  Kekre, Natasha ^a   Tokessy, Melanie ^a   Mallick, Ranjeeta ^b   McDiarmid, Sheryl ^a   Huebsch, Lothar ^a   Bredeson, Christopher ^a   Allan, David ^a   Tay, Jason ^a   Tinmouth, Alan ^a   Sheppard, Dawn ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Cytomegalovirus; Hematopoietic stem cell transplant; Leukoreduction; Transfusion

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD ANALYSIS; BLOOD BANK; BLOOD DONOR; BLOOD TRANSFUSION; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; VIREMIA; VIRUS DETECTION; VIRUS TRANSMISSION;

CYTOMEGALOVIRUS; HEMATOPOIETIC STEM CELL TRANSPLANT; LEUKOREDUCTION; TRANSFUSION;

ADULT; ANTIBODIES, VIRAL; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; PLATELETPHERESIS; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VIREMIA;

EID: 84887515875     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.09.013     Document Type: Article

References (25)

1. Yazer M.H., Podlosky L., Clarke G., Nahirniak S.M. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004, 44:10-15.
2. King K.E., Shirey R.S., Thoman S.K., et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004, 44:25-29.
3. Vamvakas E.C. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing- alloimmunization and refractoriness to random-donor platelet transfusions. Transfus Med Rev 1998, 12:258-270.
4. Paglino J.C., Pomper G.J., Fisch G.S., et al. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 2004, 44:16-24.
5. Heddle N.M., Blajchman M.A., Meyer R.M., et al. Arandomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002, 42:556-566.
6. Blajchman M.A. The clinical benefits of the leukoreduction of blood products. JTrauma 2006, 60(6 Suppl.):S83-S90.
7. de Jong M.D., Galasso G.J., Gazzard B., et al. Summary of the II International Symposium on Cytomegalovirus. Antiviral Res 1998, 39:141-162.
8. Cannon M.J., Schmid D.S., Hyde T.B. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010, 20:202-213.
9. Joseph S.A., Beliveau C., Muecke C.J., et al. Risk factors for cytomegalovirus seropositivity in a population of day care educators in Montréal, Canada. Occup Med (Lond) 2005, 55:564-567.
10. Preiksaitis J.K., Brown L., McKenzie M. The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. JInfect Dis 1988, 157:523-529.
11. Vancíková Z., Dvorák P. Cytomegalovirus infection in immunocompetent and immunocompromised individuals-a review. Curr Drug Targets Immune Endocr Metabol Disord 2001, 1:179-187.
12. Enright H., Haake R., Weisdorf D., et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 1993, 55:1339-1346.
13. Meyers J.D., Flournoy N., Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. JInfect Dis 1986, 153:478-488.
14. Saleh A.J., Al Mohareb F., Al Rabiah F., et al. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection. Hematol Oncol Stem Cell Ther 2010, 3:116-120.
15. Goodrich J.M., Bowden R.A., Fisher L., et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993, 118:173-178.
16. Bowden R.A., Sayers M., Flournoy N., et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. NEngl J Med 1986, 314:1006-1010.
17. Bowden R.A., Slichter S.J., Sayers M., et al. Acomparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995, 86:3598-3603.
18. Nichols W.G., Price T.H., Gooley T., et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003, 101:4195-4200.
19. Diaz-Mitoma F., Leger C., Miller H., et al. Comparison of DNA amplification, mRNA amplification, and DNA hybridization techniques for detection of cytomegalovirus in bone marrow transplant recipients. JClin Microbiol 2003, 41:5159-5166.
20. Boeckh M., Geballe A.P. Cytomegalovirus: pathogen, paradigm, and puzzle. JClin Invest 2011, 121:1673-1680.
21. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
22. Thiele T., Krüger W., Zimmermann K., et al. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 2011, 51:2620-2626.
23. Ziemann M., Juhl D., Görg S., Hennig H. The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients. Transfusion 2013, 53:2189-2199.
24. Ziemann M., Unmack A., Steppat D., et al. The natural course of primary cytomegalovirus infection in blood donors. Vox Sang 2010, 99:24-33.
25. Nash T., Hoffmann S., Butch S., et al. Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients. Transfusion 2012, 52:2270-2272.